Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis.

Abstract

Tanabe AAI LLC, a joint venture between Tanabe Seiyaku Co. Ltd. and aaiPharma Inc., is developing TA-2711E, an enema formulation of Tanabe's mucosal protectant ecabet, for the potential treatment of ulcerative colitis. By July 2004, phase III trials for ulcerative colitis had been initiated in Japan and phase II studies were ongoing in Europe and the U.S.; this remained the case in May 2006.

• Authors: Giovanni Monteleone, Flavio Caprioli
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 8 Issue 5 Pg. 423-8 (May 2007) ISSN: 1472-4472 [Print] England
• PMID: 17520872 (Publication Type: Journal Article, Review)

Chemical References

• Abietanes
• Anti-Inflammatory Agents
• Anti-Ulcer Agents
• ecabet

Topics

• Abietanes (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Administration, Rectal
• Animals
• Anti-Inflammatory Agents (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Anti-Ulcer Agents (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Colitis, Ulcerative (drug therapy)
• Enema
• Humans
• Treatment Outcome